XXXX (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications.

@entity1 @entity5 @entity409 @entity1933 @entity615 @entity1575 @entity157 @entity11830
@entity11830 (Resovist) is the second clinically approved superparamagnetic @entity1933 developed for contrast-enhanced MRI of the liver. The purpose of this review is to provide an overview on the properties, clinical development, and application of @entity11830 . Safety data obtained during clinical phases I-III revealed a total of 162 adverse events within 1053 @entity1 , of which 75 were classified as possibly, probably, or definitely drug related. The majority of events occurred within the first 3 h (73 of 75) and was of mild intensity. The agent significantly improves the detection of hypovascular focal @entity409 with a comparable sensitivity in lesion detection to CTAP but without a relevant loss in specificity. Furthermore, @entity11830 leads to a significant improvement of the sensitivity for lesion classification and characterization of the most frequent @entity409 . Contrast-enhanced MRA is not feasible and the angiographic effect is not sufficient to allow for postprocessing of data into maximum intensity projections. Intraindividual studies at low-field (0.2 T) and high-field (1.5 T) showed similar rates for lesion detection. The time window for contrast-enhanced MRI of the liver is at least 1 day up to 4 days. The compound can be regarded as safe and well tolerated. Even bolus injections caused no @entity615 , or clinically relevant laboratory changes. The examination time can be kept short with T1- and T2-weighted pre-contrast sequences, dynamic MRI over 10 min, and finally accumulation phase T2-weighted MRI. @entity1 who may benefit in particular are surgical candidates for resection, transplantation, or interventional therapies, and @entity1 with @entity1575 and/or suspected @entity157 to either exclude @entity5 or to define the extent of disease, the location of lesions, and the type of newly detected lesions.
